Related references
Note: Only part of the references are listed.Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013
Limin Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients
Mohsen Mazidi et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
Daisuke Ito et al.
DIABETES CARE (2017)
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Mikhail Kosiborod et al.
CIRCULATION (2017)
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action
Fernando Bril et al.
DIABETES CARE (2017)
Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study
Raymond Kwok et al.
GUT (2016)
Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes
Karen S. L. Lam et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Effect of canagliflozin on liver function tests in patients with type 2 diabetes
L. A. Leiter et al.
DIABETES & METABOLISM (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Manoela Mota et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Teruo Jojima et al.
DIABETOLOGY & METABOLIC SYNDROME (2016)
Optimal cut-off value of alanine aminotransferase level to precisely estimate the presence of fatty liver in patients with poorly controlled type 2 diabetes
Akihito Tanabe et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-A2-Glycoprotein Levels in Patients with Type 2 Diabetes
Xin Liao et al.
SCIENTIFIC REPORTS (2016)
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
Chikara Komiya et al.
PLOS ONE (2016)
Estimation of normal values of serum transaminases based on liver histology in healthy Asian Indians
Narendra S. Choudhary et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mortality From Chronic Liver Diseases in Diabetes
Giacomo Zoppini et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
F. J. Lavalle-Gonzalez et al.
DIABETOLOGIA (2013)
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort Study
Leon A. Adams et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence
HB El-Serag et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes
Zobair M. Younossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Share Paper
